Winners Announced for the RESI Innovation Challenge

22 Jan

By Nono Hu, Senior Manager, Branding & Messaging, LSN

Nono 2At LSN’s fourth Redefining Early Stage Investments (RESI) Conference, 31 selected medtech and biotech companies participated in a virtual investment contest: The RESI Innovation Challenge. RESI Innovators showcased cutting-edge life science technologies in poster displays throughout the exhibit hall, competing to raise the most RESI Cash.

The winners are in. Congratulations!

First Prize Winner: Kineta


Kineta is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. The company is focused on the development of novel drug candidates, each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed, NIH-supported research.

kineta 1st

Rob Hedequist, Senior Vice President, Corporate Development, Kineta
 Bill Brah, Executive Director, UMass Venture Development Center

As a first prize winner, Kineta will receive complimentary subscription to the LSN Investor Platform.

Second Prize Winner: Transverse Medical


Transverse Medical, Inc. is an early stage medical technology company in the evolving and rapidly growing area of Transcatheter Aortic Valve Replacement (TAVR). The TAVR procedure, along with other cardiovascular interventional and surgical procedures, is in need of cerebral protection options. TMI is meeting this need and the challenge of preventing neurocognitive stroke events during TAVR and other such procedures through development of the Point-Guard™ Cerebral Embolic Protection Device.

transverse 2nd

Eric Goslau, CEO, Transverse Medical

Third Prize Winner: Amorphex Therapeutics


Amorphex Therapeutics was founded in 2010 to develop and license products for sustained ophthalmic drug delivery using the TODDD™ technology developed by Vista Scientific, LLC. The TODDD™ technology platform is an ocular insert for sustained delivery of drugs to the eye. This patented insert is based on controlled delivery polymer systems and a unique product design utilizing advanced comfort and stability features. In addition to the matrix materials that are used for controlled delivery, the TODDD™ device is also able to incorporate relatively large drug depots for the delivery of specific drugs. This affords the ability to deliver multiple drugs simultaneously. 

amorphex 3th

Robert Thompson, President & CEO, Amorphex Therapeutics
Bill Brah, Executive Director, UMass Venture Development Center
Charles Leahy, Vice President, Clinical Affairs, Amorphex Therapeutics

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: